nach oben

Current Oncology Reports

Erschienen in:

01.06.2021 | Breast Cancer (AS Zimmer, Section Editor)

Managing Common Estrogen Deprivation Side Effects in HR+ Breast Cancer: an Evidence-Based Review

verfasst von: Bethânia Soares dos Santos, Cláudia Bordignon, Daniela Dornelles Rosa

Erschienen in: Current Oncology Reports | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The article reviews the consequences of estrogen deprivation during endocrine therapy for breast cancer and provides an update on alternative therapies for the management of symptoms.

Recent Findings

Endocrine therapy has progressed substantially in recent years, and its use is recommended for all breast cancer patients expressing hormone receptors. The main adverse events of this treatment can be controlled with medications and nonpharmacological measures. Antidepressants are effective in controlling vasomotor symptoms. Vaginal discomfort can be treated with local lubricants and pelvic floor physiotherapy, which may help in sexual dysfunction. Pathophysiological mechanisms of musculoskeletal symptoms during aromatase inhibitors treatment are not well understood, but some studies evaluating treatment with duloxetine, yoga, and acupuncture have shown some benefits. For prevention of bone loss, patients with risk factors should be offered bisphosphonates or denosumab.

Summary

Individualization of treatment is crucial. Consideration should be given to therapy effects on quality of life, and strategies for controlling associated symptoms should be offered.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84. https://doi.org/10.1016/S0140-6736(11)60993-8.CrossRef

Moon Z, Moss-Morris R, Hunter MS, Carlisle S, Hughes LD. Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. Patient Prefer Adherence. 2017;11:305–22. https://doi.org/10.2147/PPA.S126651.CrossRefPubMedPubMedCentral

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet Lond Engl. 2005;365(9472):1687–717.CrossRef

Pistilli B, Paci A, Ferreira AR, Di Meglio A, Poinsignon V, Bardet A, et al. Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk. J Clin Oncol. 2020;38(24):2762–72. https://doi.org/10.1200/JCO.19.01758.CrossRefPubMed

Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005;23(28):6931–40. https://doi.org/10.1200/JCO.2005.11.181.CrossRefPubMed

Lemieux J, Brundage MD, Parulekar WR, Goss PE, Ingle JN, Pritchard KI, et al. Quality of life from Canadian cancer trials group MA.17R: a randomized trial of extending adjuvant letrozole to 10 years. J Clin Oncol. 2018;36(6):563–71. https://doi.org/10.1200/JCO.2017.75.7500.CrossRefPubMedPubMedCentral

Regan MM, Price KN, Giobbie-Hurder A, Thürlimann B, Gelber RD, International Breast Cancer Study Group and BIG 1-98 Collaborative Group. Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Res. 2011;13(3):209. https://doi.org/10.1186/bcr2837.CrossRefPubMedPubMedCentral

Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, et al. Austrian breast and colorectal cancer study group. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007;99(24):1845–53. https://doi.org/10.1093/jnci/djm246.CrossRefPubMed

•• Burstein HJ, Lacchetti C, Griggs JJ. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Oncol Pract. 2019;15(2):106–7. https://doi.org/10.1200/JOP.18.00617This is a systematic review of randomized clinical trials from 2012 to 2018 on adjuvant endocrine therapy. The study demonstrated that extension of aromatase inhibitors treatment is associated with increased adverse effects that may affect quality of life. Extension of adjuvant endocrine treatment should be based on considerations of recurrence risk using established prognostic factors.CrossRefPubMed

10.

Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women’s health across the nation. Am J Public Health. 2006;96(7):1226–35. https://doi.org/10.2105/AJPH.2005.066936.CrossRefPubMedPubMedCentral

11.

Goldfarb S, Mulhall J, Nelson C, Kelvin J, Dickler M, Carter J. Sexual and reproductive health in cancer survivors. Semin Oncol. 2013;40(6):726–44. https://doi.org/10.1053/j.seminoncol.2013.09.002.CrossRefPubMed

12.

Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet. 2000;356(9247):2059–63. https://doi.org/10.1016/S0140-6736(00)03403-6.CrossRefPubMed

13.

Johns C, Seav SM, Dominick SA, Gorman JR, Li H, Natarajan L, et al. Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions. Breast Cancer Res Treat. 2016;156(3):415–26. https://doi.org/10.1007/s10549-016-3765-4.CrossRefPubMedPubMedCentral

14.

Shams T, Firwana B, Habib F, Alshahrani A, Alnouh B, Murad MH, et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med. 2014;29(1):204–13. https://doi.org/10.1007/s11606-013-2535-9.CrossRefPubMed

15.

Condorelli R, Vaz-Luis I. Managing side effects in adjuvant endocrine therapy for breast cancer. Expert Rev Anticancer Ther. 2018;18(11):1101–12. https://doi.org/10.1080/14737140.2018.1520096.CrossRefPubMed

16.

Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, Pajon E, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 2005;366(9488):818–24. https://doi.org/10.1016/S0140-6736(05)67215-7.CrossRefPubMedPubMedCentral

17.

Shan D, Zou L, Liu X, Shen Y, Cai Y, Zhang J. Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020;222(6):564–579.e12. https://doi.org/10.1016/j.ajog.2019.12.011.CrossRefPubMed

18.

Sica DA, Grubbs R. Transdermal clonidine: therapeutic considerations. J Clin Hypertens (Greenwich). 2005;7(9):558–62. https://doi.org/10.1111/j.1524-6175.2005.04133.x.CrossRef

19.

Prague JK, Roberts RE, Comninos AN, Clarke S, Jayasena CN, Nash Z, et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10081):1809–20. https://doi.org/10.1016/S0140-6736(17)30823-1.CrossRefPubMedPubMedCentral

20.

Pinkerton JV, Santen RJ. Managing vasomotor symptoms in women after cancer. Climacteric. 2019;22(6):544–52. https://doi.org/10.1080/13697137.2019.1600501.CrossRefPubMed

21.

Tran S, Hickey M, Saunders C, Ramage L, Cohen PA. Nonpharmacological therapies for the management of menopausal vasomotor symptoms in breast cancer survivors. Support Care Cancer. 2020;29:1183–93. https://doi.org/10.1007/s00520-020-05754-w.CrossRefPubMed

22.

McCormick CA, Brennan A, Hickey M. Managing vasomotor symptoms effectively without hormones. Climacteric. 2020;22:1–7. https://doi.org/10.1080/13697137.2020.1789093.CrossRef

23.

Cramer H, Peng W, Lauche R. Yoga for menopausal symptoms-a systematic review and meta-analysis. Maturitas. 2018;109:13–25. https://doi.org/10.1016/j.maturitas.2017.12.005.CrossRefPubMed

24.

•• Marsden J, Marsh M, Rigg A, British Menopause Society. British Menopause Society consensus statement on the management of estrogen deficiency symptoms, arthralgia and menopause diagnosis in women treated for early breast cancer. Post Reprod Health. 2019;25(1):21–32. https://doi.org/10.1177/2053369118824920This guidance provides an overview of the management strategies of estrogen deficiency symptoms associated with breast cancer treatment.CrossRefPubMed

25.

Santen RJ, Stuenkel CA, Davis SR, Pinkerton JV, Gompel A, Lumsden MA. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. J Clin Endocrinol Metab. 2017;102(10):3647–61. https://doi.org/10.1210/jc.2017-01138.CrossRefPubMed

26.

Baumgart J, Nilsson K, Stavreus-Evers A, Kask K, Villman K, Lindman H, et al. Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer. Am J Obstet Gynecol. 2011;204(1):26.e1–7. https://doi.org/10.1016/j.ajog.2010.08.035.CrossRef

27.

Faubion SS, Loprinzi CL, Ruddy KJ. Management of hormone deprivation symptoms after cancer. Mayo Clin Proc. 2016;91(8):1133–46. https://doi.org/10.1016/j.mayocp.2016.04.009.CrossRefPubMed

28.

Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2015;33(30):3394–400. https://doi.org/10.1200/JCO.2014.60.7366.CrossRefPubMedPubMedCentral

29.

American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice, Farrell R. ACOG Committee Opinion No. 659: The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol. 2016;127(3):e93–6. https://doi.org/10.1097/AOG.0000000000001351.CrossRef

30.

Knight C, Logan V, Fenlon D. A systematic review of laser therapy for vulvovaginal atrophy/genitourinary syndrome of menopause in breast cancer survivors. Ecancermedicalscience. 2019;13:988. https://doi.org/10.3332/ecancer.2019.988.CrossRefPubMedPubMedCentral

31.

Flynn KE, Reese JB, Jeffery DD, Abernethy AP, Lin L, Shelby RA, et al. Patient experiences with communication about sex during and after treatment for cancer. Psychooncology. 2012;21(6):594–601. https://doi.org/10.1002/pon.1947.CrossRefPubMed

32.

Beckwée D, Leysen L, Meuwis K, Adriaenssens N. Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis. Support Care Cancer. 2017;25(5):1673–86. https://doi.org/10.1007/s00520-017-3613-z.CrossRefPubMed

33.

Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. Breast. 2007;16(3):223–34. https://doi.org/10.1016/j.breast.2007.01.011.CrossRefPubMed

34.

• Roberts KE, Rickett K, Feng S, Vagenas D, Woodward NE. Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer. Cochrane Database Syst Rev. 2020;1(1):CD012988. https://doi.org/10.1002/14651858.CD012988.pub2In this systematic review and meta-analysis of 7 studies, authors have not found any clear evidence of benefit for exercise therapies for preventing or treating women with breast cancer and aromatase inhibitor-induced musculoskeletal symptoms.CrossRefPubMed

35.

Peppone LJ, Janelsins MC, Kamen C, Mohile SG, Sprod LK, Gewandter JS, et al. The effect of YOCAS©® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy. Breast Cancer Res Treat. 2015;150(3):597–604. https://doi.org/10.1007/s10549-015-3351-1.CrossRefPubMedPubMedCentral

36.

Chien TJ, Liu CY, Chang YF, Fang CJ, Hsu CH. Acupuncture for treating aromatase inhibitor-related arthralgia in breast cancer: a systematic review and meta-analysis. J Altern Complement Med. 2015;21(5):251–60. https://doi.org/10.1089/acm.2014.0083.CrossRefPubMedPubMedCentral

37.

Hershman DL, Unger JM, Heather Greenlee ND, et al. Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer - a randomized clinical trial. JAMA. 2018;320(2):167–76. https://doi.org/10.1001/jama.2018.8907.CrossRefPubMedPubMedCentral

38.

Gupta A, Henry NL, Loprinzi CL. Management of aromatase inhibitor-induced musculoskeletal symptoms. JCO Oncol Pract. 2020;11:OP2000113. https://doi.org/10.1200/OP.20.00113.CrossRef

39.

Hershman DL, Unger JM, Crew KD, Awad D, Dakhil SR, Gralow J, et al. Randomized multicenter placebo-controlled trial of omega-3 fatty acids for the control of aromatase inhibitor-induced musculoskeletal pain: SWOG S0927. J Clin Oncol. 2015;33(17):1910–7. https://doi.org/10.1200/JCO.2014.59.5595.CrossRefPubMedPubMedCentral

40.

Shen S, Unger JM, Crew KD, Till C, Greenlee H, Gralow J, et al. Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). Breast Cancer Res Treat. 2018;172(3):603–10. https://doi.org/10.1007/s10549-018-4946-0.CrossRefPubMedPubMedCentral

41.

Rastelli AL, Taylor ME, Gao F, Armamento-Villareal R, Jamalabadi-Majidi S, Napoli N, et al. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Res Treat. 2011;129(1):107–16. https://doi.org/10.1007/s10549-011-1644-6.CrossRefPubMed

42.

Khan QJ, Kimler BF, Reddy PS, Sharma P, Klemp JR, Nydegger JL, et al. Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial. Breast Cancer Res Treat. 2017;166(2):491–500. https://doi.org/10.1007/s10549-017-4429-8.CrossRefPubMed

43.

Shapiro AC, Adlis SA, Robien K, Kirstein MN, Liang S, Richter SA, et al. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). Breast Cancer Res Treat. 2016;155(3):501–12. https://doi.org/10.1007/s10549-016-3710-6.CrossRefPubMedPubMedCentral

44.

• Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, et al. Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202. J Clin Oncol. 2018;36(4):326–32. https://doi.org/10.1200/JCO.2017.74.6651This randomized, double blind, phase 3 study compares duloxetine to placebo for AIMSS in breast cancer patients. By 12 weeks, pain and functioning scores were better for patients receiving duloxetine.CrossRefPubMed

45.

Henry NL, Unger JM, Till C, Schott AF, Crew KD, Lew DL, et al. Association between body mass index and response to duloxetine for aromatase inhibitor-associated musculoskeletal symptoms in SWOG S1202. Cancer. 2019;125(12):2123–9. https://doi.org/10.1002/cncr.32024.CrossRefPubMedPubMedCentral

46.

Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat. 2010;120(1):127–34. https://doi.org/10.1007/s10549-009-0692-7.CrossRefPubMed

47.

Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(1):127–38. https://doi.org/10.1016/S1470-2045(17)30715-5.CrossRefPubMed

48.

Ramchand SK, Cheung YM, Yeo B, Grossmann M. The effects of adjuvant endocrine therapy on bone health in women with breast cancer. J Endocrinol. 2019;241(3):R111–24. https://doi.org/10.1530/JOE-19-0077.CrossRefPubMed

49.

Tseng OL, Spinelli JJ, Gotay CC, Ho WY, McBride ML, Dawes MG. Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis. 2018;10(4):71–90. https://doi.org/10.1177/1759720X18759291.CrossRefPubMedPubMedCentral

50.

Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, et al. Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol. 2017;7:1–12. https://doi.org/10.1016/j.jbo.2017.03.001.CrossRefPubMedPubMedCentral

51.

•• Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol. 2019;37(31):2916–46. https://doi.org/10.1200/JCO.19.01696Although this ASCO guideline provides recommendations for management of osteoporosis in all survivors of adult cancer, many studies reviewed have included breast cancer patients treated with endocrine therapy. Therefore, its recommendations can be applied only for this group of patients.CrossRefPubMed

52.

Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, et al. Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol. 2020. In press;31:1650–63. https://doi.org/10.1016/j.annonc.2020.07.019.CrossRefPubMed

53.

Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 2011;7:CD000333. https://doi.org/10.1002/14651858.CD000333.pub2.CrossRef

54.

Dalla Via J, Daly RM, Fraser SF. The effect of exercise on bone mineral density in adult cancer survivors: a systematic review and meta-analysis. Osteoporos Int. 2018;29(2):287–303. https://doi.org/10.1007/s00198-017-4237-3.CrossRefPubMed

55.

Fornusek CP, Kilbreath SL. Exercise for improving bone health in women treated for stages I-III breast cancer: a systematic review and meta-analyses. J Cancer Surviv. 2017;11(5):525–41. https://doi.org/10.1007/s11764-017-0622-3.CrossRefPubMed

56.

Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer. 2012;118(5):1192–201. https://doi.org/10.1002/cncr.26313.CrossRefPubMed

57.

Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013;24(2):398–405. https://doi.org/10.1093/annonc/mds277.CrossRefPubMed

58.

Mei M, Xiang Z, Yang J, Xiang R. Efficacy of zoledronic acid for prevention of bone loss in early-stage breast cancer patients receiving adjuvant therapy: a meta-analysis of 13 randomized controlled trials. Curr Probl Cancer. 2020;44(2):100507. https://doi.org/10.1016/j.currproblcancer.2019.100507.CrossRefPubMed

59.

Early Breast Cancer. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386(10001):1353–61. https://doi.org/10.1016/S0140-6736(15)60908-4.CrossRef

60.

Sestak I, Blake GM, Patel R, Coleman RE, Cuzick J, Eastell R. Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. Bone. 2019;124:83–8. https://doi.org/10.1016/j.bone.2019.04.016.CrossRefPubMedPubMedCentral

61.

Livi L, Scotti V, Desideri I, Saieva C, Cecchini S, Francolini G, et al. Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial. Eur J Cancer. 2019;108:100–10. https://doi.org/10.1016/j.ejca.2018.12.005.CrossRefPubMed

62.

Kyvernitakis I, Kann PH, Thomasius F, Hars O, Hadji P. Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial. Bone. 2018;114:109–15. https://doi.org/10.1016/j.bone.2018.06.007.CrossRefPubMed

63.

Wagner-Johnston ND, Sloan JA, Liu H, Kearns AE, Hines SL, Puttabasavaiah S, et al. 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer. 2015;121(15):2537–43. https://doi.org/10.1002/cncr.29327.CrossRefPubMedPubMedCentral

64.

Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9992):433–43. https://doi.org/10.1016/S0140-6736(15)60995-3.CrossRefPubMed

65.

Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(1):60–72. https://doi.org/10.1016/S1470-2045(19)30687-4.CrossRefPubMed

66.

Johansson H, Gray KP, Pagani O, Regan MM, Viale G, Aristarco V, et al. Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast Cancer Res. 2016;18(1):110. https://doi.org/10.1186/s13058-016-0771-8.CrossRefPubMedPubMedCentral

67.

Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman JA, et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol. 2010;28(31):4674–82. https://doi.org/10.1200/JCO.2010.28.5064.CrossRefPubMedPubMedCentral

68.

US Food and Drug Administration. FDA warns against use of energy-based devices to perform vaginal ‘rejuvenation’ or vaginal cosmetic procedures: FDA safety communication

Titel: Managing Common Estrogen Deprivation Side Effects in HR+ Breast Cancer: an Evidence-Based Review
verfasst von: Bethânia Soares dos Santos
Cláudia Bordignon
Daniela Dornelles Rosa
Publikationsdatum: 01.06.2021
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 6/2021
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-021-01055-5

Springer Medizin

Managing Common Estrogen Deprivation Side Effects in HR+ Breast Cancer: an Evidence-Based Review

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

Erythroleukemia: an Update

Role of Machine Learning and Artificial Intelligence in Interventional Oncology

Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy

Organizational Strategies for Providing Cancer Palliative Care to Many

Extracellular vesicles and their associated miRNAs as potential prognostic biomarkers in chronic lymphocytic leukemia

Update on Osteosarcoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie